-
Torrent Pharmaceuticals vs Windlas Biotech Growth: Which Branded and Contract Formulations Wins
- July 23, 2026
- Posted by: Kunal Singla
- Category: News
No Comments
Torrent Pharmaceuticals vs Windlas Biotech growth compares concentrated cardiac and CNS therapeutic branded formulations leadership against concentrated domestic contract manufacturing for branded generics to see which branded and contract formulations has better growth.
-
Mankind Pharma vs JB Chemicals Business Model: Which Domestic Branded Formulations Wins
- July 23, 2026
- Posted by: Kunal Singla
- Category: News
Mankind Pharma vs JB Chemicals business model compares scale-led domestic branded generics combined with consumer healthcare products against concentrated cardiac and gastro-intestinal therapeutic branded formulations to see which domestic branded formulations has better business model.
-
ABSL Credit Risk Regular Bonus: NAV Today, Performance Review and Should You Invest?
- July 23, 2026
- Posted by: Neeraj Pandey
- Category: Mutual Funds
ABSL Credit Risk Regular Bonus NAV, latest returns and full review including risks and how to invest.
-
ABSL Credit Risk Direct Bonus: NAV Today, Performance Review and Should You Invest?
- July 23, 2026
- Posted by: Neeraj Pandey
- Category: Mutual Funds
ABSL Credit Risk Direct Bonus NAV, latest returns and full review including risks and how to invest.
-
Zydus Lifesciences Share Price Watched as Company Gets Nod for Desidustat Phase III Sickle Cell Trial
- July 23, 2026
- Posted by: Kunal Singla
- Category: News
Zydus Lifesciences share price is in focus after the company received approval to conduct a Phase III trial of Desidustat for sickle cell disease. Check CMP here.
-
Bharat Forge Share Price Watched as Kalyani Powertrain Agrees to Divest Stake in REFU Drive GmBH
- July 23, 2026
- Posted by: Kunal Singla
- Category: News
Bharat Forge share price is in focus after subsidiary Kalyani Powertrain agreed to sell its 50 percent stake in REFU Drive GmBH. Check CMP and details here.
-
ABSL Corporate Bond Regular Monthly IDCW: NAV Today, Performance Review and Should You Invest?
- July 23, 2026
- Posted by: Neeraj Pandey
- Category: Mutual Funds
ABSL Corporate Bond Regular Monthly IDCW NAV, latest returns and full review including risks and how to invest.
-
Nifty Pharma Index Extends Losses for Second Straight Session as Dr Reddy’s Leads Declines
- July 23, 2026
- Posted by: Kunal Singla
- Category: News
Nifty Pharma index extends losses for a second straight session today, with Dr Reddy’s, Ajanta Pharma and Biocon among the top losers. Check the full list here.
-
ITC Hotels vs Indian Hotels Company Business Model: Which Hotels and Hospitality Wins
- July 23, 2026
- Posted by: Ankit Jaiswal
- Category: News
ITC Hotels vs Indian Hotels Company business model compares recently independent hotel operations with ITC brand heritage against established Tata Group luxury and premium hotel portfolio under Taj brand to see which hotels and hospitality has better business model.
-
Ajanta Pharma vs Torrent Pharmaceuticals Growth: Which Domestic Branded Formulations Wins
- July 23, 2026
- Posted by: Ankit Jaiswal
- Category: News
Ajanta Pharma vs Torrent Pharmaceuticals growth compares concentrated ophthalmology therapeutic focus with meaningful export exposure against concentrated cardiac and CNS therapeutic branded formulations leadership to see which domestic branded formulations has better growth.